揭示并利用CD39通过工程化T细胞治疗结直肠癌及肝转移
本研究通过多维方法分析原发性和转移性结直肠癌中T细胞的功能景观,发现CD39是耗竭的主要驱动因素。利用TCR编辑和CRISPR/Cas9破坏CD39基因,生成靶向HER-2的工程化T细胞,在体外和体内均显示对HER-2阳性患者来源类器官的清除优势。
要点
- 肿瘤浸润T细胞共表达多种抑制性受体,原发灶与转移灶差异显著。
- CD39是原发性和转移性结直肠肿瘤中T细胞耗竭的主要驱动因素。
- CD39缺失的HER-2特异性T细胞在体外和体内均具有功能优势。
核心结论
- HER-2特异性CD39破坏的工程化T细胞是原发性和转移性结直肠癌有前景的先进医药产品。
研究设计与样本
- 研究采用高维流式细胞术、RNA测序和免疫组化描述原发性和转移性结直肠癌患者健康与肿瘤组织中T细胞的功能表型。
- 应用慢病毒载体和CRISPR/Cas9基因组编辑技术开发结直肠癌特异性细胞产品。
主要发现
- T细胞主要定位于肿瘤前沿,肿瘤浸润T细胞共表达多种抑制性受体,原发灶与转移灶差异很大。
- CD39是原发性和转移性结直肠肿瘤中T细胞耗竭的主要驱动因素。
- 同时重定向T细胞特异性靶向HER-2并破坏内源性TCR基因和CD39编码基因,生成TCREDENTPD1KOHER-2重定向淋巴细胞。
- CD39缺失赋予HER-2特异性T细胞在体外和体内清除HER-2阳性患者来源类器官的功能优势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Colorectal tumours are often densely infiltrated by immune cells that have a role in surveillance and modulation of tumour progression but are burdened by immunosuppressive signals, which might vary from primary to metastatic stages. Here, we deployed a multidimensional approach to unravel the T-cell functional landscape in primary colorectal cancers (CRC) and liver metastases, and genome editing tools to develop CRC-specific engineered T cells. DESIGN: We paired high-dimensional flow cytometry, RNA sequencing and immunohistochemistry to describe the functional phenotype of T cells from healthy and neoplastic tissue of patients with primary and metastatic CRC and we applied lentiviral vectors (LV) and CRISPR/Cas9 genome editing technologies to develop CRC-specific cellular products. RESULTS: We found that T cells are mainly localised at the front edge and that tumor-infiltrating T cells co-express multiple inhibitory receptors, which largely differ from primary to metastatic sites. Our data highlighted CD39 as the major driver of exhaustion in both primary and metastatic colorectal tumours. We thus simultaneously redirected T-cell specificity employing a novel T-cell receptor targeting HER-2 and disrupted the endogenous TCR genes (TCR editing (TCRED)) and the CD39 encoding gene (ENTPD1), thus generating TCREDENTPD1KOHER-2-redirected lymphocytes. We showed that the absence of CD39 confers to HER-2-specific T cells a functional advantage in eliminating HER-2+ patient-derived organoids in vitro and in vivo. CONCLUSION: HER-2-specific CD39 disrupted engineered T cells are promising advanced medicinal products for primary and metastatic CRC.
引用
- Potenza A, Balestrieri C, Spiga M, et al. Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells. Gut. 2023. PMID: 37399271. doi:10.1136/gutjnl-2022-328042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。